The US market is yet to commence its session on Thursday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) reported Q2 CY2025 results topping the market’s revenue expectations, with sales up 8.5% year on year to $240.7 million. The company expects the full year’s revenue to be around $1 billion, close to analysts’ estimates. Its GAAP loss of $0.78 per share was significantly below analysts’ consensus estimates.
Tandem Diabetes Care reported mixed Q2 2025 results with revenue growth but a wider loss, causing a stock drop. Updated guidance reflects R&D costs and operational progress.
Let's have a look at what is happening on the US markets after the closing bell on Wednesday. Below you can find the top gainers and losers in today's after hours session.
Diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM)
will be reporting earnings this Wednesday after the bell. Here’s what investors should know.
Wall Street has set ambitious price targets for the stocks in this article.
While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
Shares of diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM)
jumped 5.4% in the morning session after the stock appeared to rebound from a recent 52-week low as investors looked ahead to its upcoming quarterly earnings report. The upward movement followed the stock hitting a 52-week low just ten days prior, a level that may have attracted investors looking for a potential bargain. Market participants were also likely positioning themselves ahead of Tandem's second-quarter 2025 financial results, which the company had announced would be released on August 6. The move occurred amidst mixed signals from financial analysts in the preceding weeks. For instance, Canaccord Genuity had raised its price target, citing strong performance, while Citi had downgraded the stock due to competitive concerns.
A number of stocks jumped in the afternoon session after a new trade agreement between the United States and Japan spurred a broad market rally. The positive sentiment swept across markets after it was announced the U.S. and Japan had reached a new trade deal. The agreement included a 15% tariff on Japanese goods imported into the U.S. and a commitment from Japan to invest $550 billion in the U.S. and open its markets to American cars and agricultural products. This development boosted investor confidence and contributed to a widespread rally, lifting stocks across many sectors. The Dow Jones Industrial Average and the S&P 500 both posted gains, creating a favorable environment that likely benefited individual stocks.
A number of healthcare stocks fell in the afternoon session after several negative developments weighed on the sector. Weakness in managed care providers was a significant factor, with companies like Elevance Health and Humana seeing declines due to an analyst downgrade and a lost lawsuit regarding Medicare bonus payments, respectively.
The past year hasn't been kind to the stocks featured in this article.
Each has tumbled to their lowest points in 12 months, leaving investors to decide whether they're witnessing fire sales or falling knives.
A number of stocks fell in the afternoon session after the U.S. administration announced a sharp escalation in trade tensions by threatening new tariffs on Canada. The wider market sentiment turned negative after the White House announced plans to impose a 35% tariff on Canadian imports, sparking renewed fears of a trade war. This news prompted a sell-off across major U.S. indexes, including the S&P 500 and the Dow Jones Industrial Average, as investors grew concerned about the potential economic impact of escalating protectionist policies.
The healthcare sector is especially vulnerable to such tensions due to its deeply integrated supply chains with Canada for pharmaceuticals and medical devices, meaning increased costs and potential disruptions.
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings.
However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats.
Shares of diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM)
fell 3.5% in the morning session after a Citi analyst downgraded the stock. Citi analyst Joanna Wuensch downgraded Tandem Diabetes Care from a "Neutral" to a "Sell" rating and significantly cut the price target on the shares to $24 from $35. This move signals rising concerns about the company's future performance and competitive position in the diabetes technology market.
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead.
They also usually carry less risk than penny stocks, though they’re not immune to volatility as many lack the scale advantages of their larger peers.
Growth is a hallmark of all great companies, but the laws of gravity eventually take hold.
Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s punishment can be swift and severe when trajectories fall.
